Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MELD-ATG: Low-Dose ATG in New-Onset T1D
NCT04509791Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Nov 2020
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of antithymocyte globulin rabbit in type 1 diabetes mellitus (T1D) (5 arms), sponsored by UZ Leuven. Primary endpoint: Area Under the Stimulated C-peptide Response Curve at 12 months. Started Nov 2020; status: completed.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04509791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04509791.